Custom PEG synthesis JenKem Technology provides high quality heterobifunctional polyethylene glycol derivatives (PEGs) with high purity and low polydispersity.

JenKem Technology’s heterobifunctional PEG derivatives are generally employed as crosslinking agents or as spacers between two different chemical entities. The PEG moiety in the heterobifunctional PEG derivatives provides water solubility, biocompatibility, and flexibility to the linker. Linear heterobifunctional PEG derivatives have the following general structure:

X―PEG―Y

where X and Y are two different functional reactive groups.

JenKem Technology’s multi-arm heterofunctional PEG Derivatives are also useful as linkers for Antibody-Drug Conjugates. ADCs conjugated via heterobifunctional PEGs exhibit improved water solubility and PK/PD profile.

Heterobifunctional PEG products with molecular weights and functional groups not listed in our online catalog may be available by custom synthesis. Please inquire at tech@jenkemusa.com about pricing and availability of custom heterobifunctional PEGs.

JenKem Technology provides GMP grade PEG derivatives and bulk orders via custom synthesis, offering the opportunity to match customers’ special quality requirements. JenKem Technology is capable of development and synthesis of a wide range of GMP PEG derivatives starting at 200g up to 40 kg or greater batches, under ISO 9001 and ISO 13485 certified quality management system, following ICH Q7A guidelines. For inquiries on cGMP production of PEG derivatives please contact us at tech@jenkemusa.com.

For global distribution, please visit link. Please click the buttons below to order directly from JenKem Technology:

PEG PRODUCT PURITY REACTIVITY DETAILS
≥95% Hydroxyl PEG Carboxyl (Hydroxyl PEG Acetic Acid, HO-PEG-CM, HO-PEG-COOH). COOH group is stable and can be activated [1, 2, 12]
≥95% Hydroxyl PEG Succinimidyl Carboxymethyl Ester (HO-PEG-NHS). Crosslinking reagent, the activated form of HO-PEG-COOH [3, 4]
≥95% Hydroxyl PEG Propionic Acid (Hydroxyl PEG Propanoic Acid, HO-PEG-PA). COOH group is stable and can be activated
≥95% Hydroxyl PEG Succinimidyl Propionate (Hydroxyl PEG Succinimidyl Propanoate, HO-PEG-SPA). Crosslinking reagent, the activated form of HO-PEG-PA
≥95% Hydroxyl PEG Hexanoic Acid (HO-PEG-HA). COOH group is stable and can be activated
≥95% Hydroxyl PEG Amine (HO-PEG-NH2). NH2 group is stable and can be activated [8]
≥95% Thiol PEG Carboxyl (HS-PEG-COOH, Thiol PEG Acetic Acid, HS-PEG-CM). HS is thiol reactive, while COOH is stable and can be activated [5, 6]
≥95% Thiol PEG Succinimidyl Propionate (HS-PEG-SPA). HS is thiol reactive while COOH is stable and can be activated [42]
>90% Thiol PEG Succinimidyl Glutaramide (HS-PEG-SGA). Crosslinking PEG reagent. Longer hydrolysis half-life compared to the SCM NHS PEG ester. [7]
≥95% Thiol PEG Amine (HS-PEG-NH2). HS is thiol reactive and NH2 is stable and can be activated [9]
≥95% Amine PEG Carboxyl (NH2-PEG-COOH). Both COOH and NH2 groups are stable and can be activated [10, 11, 40, 41]
≥95% TBOC Amine PEG Hydroxyl (TBOC-PEG-OH). Crosslinking PEG reagent. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [2]
≥95% TBOC Amine PEG Amine (TBOC-PEG-NH2). Crosslinking PEG reagent. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [13]
≥95% TBOC Amine PEG Carboxyl (TBOC-PEG-COOH, TBOC-PEG-CM, TBOC PEG Acetic Acid). Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [15]
>90% TBOC Amine PEG SCM Ester (TBOC-PEG-SCM, TBOC-PEG-NHS, ). Crosslinking PEG for ADC development. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [18]
≥95% FMOC Amine PEG Hydroxyl (FMOC-PEG-OH) Crosslinking PEG reagent. The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [43]
≥95% FMOC Amine PEG Amine (FMOC-PEG-NH2). Crosslinking PEG reagent. 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [14]
≥95% FMOC Amine PEG Carboxyl (FMOC-PEG-COOH, FMOC-PEG-CM, FMOC-PEG-Acetic Acid). The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [16, 17]
>90% FMOC Amine PEG NHS Ester (FMOC-PEG-SCM, FMOC-PEG-NHS). The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [19]
>90% Acrylate PEG NHS Ester (ACLT-PEG-NHS, ACLT-PEG-SCM). Light sensitive PEG, will crosslink with exposure to ultraviolet light [20-22]
>90% Acrylate PEG Succinimidyl Propionate (ACLT-PEG-SPA). Light sensitive PEG, will crosslink with exposure to ultraviolet light
≥95% Maleimide PEG Hydroxyl (MAL-PEG-OH). Maleimide is thiol reactive and Hydroxyl is stable [23]
≥95% Maleimide PEG Amine (MAL-PEG-NH2). Maleimide is thiol reactive and Amine is stable and can be activated [24, 45-47]
≥95% Maleimide PEG Carboxyl (MAL-PEG-CM, MAL-PEG-COOH). Maleimide is thiol reactive and Carboxyl is stable and can be activated [25]
>90% Maleimide PEG NHS Ester, or Maleimide PEG SCM, the activated form of MAL-PEG-COOH [26-31]
>90% Biotin PEG SCM Ester. Biotin can be attached to avidin-containing surfaces or molecules; NHS ester reacts with amine groups [32]
≥95% Biotin PEG Maleimide. Crosslinking reagent for ADC development. Biotin can be attached to avidin-containing surfaces or molecules; Maleimide group is thiol reactive [33]
≥95% Biotin PEG Succinimidyl Glutaramide. Biotin can be attached to avidin-containing surfaces or molecules; SGA has a longer hydrolysis half-life compared with SCM NHS Ester [38]
>90% OPSS PEG NHS Ester. Ortho-pyridyl disulfide (OPSS) is thiol reactive; NHS ester can be reacted with Amine groups [34]
>90% Azide PEG NHS Ester. The Azide group may be reduced to amine by hydrogenolysis; Click chemistry PEG reagent for reaction with alkynes [35, 44]
≥95% Azide PEG Amine. The Azide group may be reduced to amine by hydrogenolysis; Click PEG reagent for reaction with alkynes [36]
≥95% Alkyne PEG Maleimide. Click PEG reagent for reaction with azides [37]

Monodisperse (Discrete) Heterobifunctional PEGs

Multiarm Heterobifunctional (3ARM, 4ARM, 6ARM and 8ARM PEGs) 

Linear PEG Raw Materials (Methoxy PEG Hydroxyl and Benzyl PEG Hydroxyl)

PEG RAW MATERIALS MAIN PEAK FRACTION BY GPC POLYDISPERSITY BY GPC
≥95% ≤ 1.05-1.10
≥95% ≤ 1.05

References:

  1. Abstiens, K., et al., Gold-tagged Polymeric Nanoparticles with Spatially Controlled Composition for Enhanced Detectability in Biological Environments, ACS Applied Nano Materials, 2019.
  2. Abstiens, K., et al., Interaction of functionalized nanoparticles with serum proteins and its impact on colloidal stability and cargo leaching, Soft matter., 2019.
  3. Dutta, R., et al., Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice, Pharmaceutical research, 2017, 34(3):564-78.
  4. Wang, Y., et al., A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries, Journal of Controlled Release, 2020.
  5. Tapia-Arellano, A., et al., Functionalization with PEG/Angiopep-2 peptide to improve the delivery of gold nanoprisms to central nervous system: in vitro and in vivo studies, Materials Science and Engineering: C, 2021, 121, 111785.
  6. Zhao, B., et al., Single-step, wash-free digital immunoassay for rapid quantitative analysis of serological antibody against SARS-CoV-2 by photonic resonator absorption microscopy, Talanta, 2021, 225, 122004.
  7. Barros, D., et al., An affinity-based approach to engineer laminin-presenting cell instructive microenvironments, Biomaterials, 2019, 192:601-11.
  8. Peters, M., et al., PEGylating poly(p-phenylene vinylene)-based bioimaging nanoprobes, Journal of Colloid and Interface Science, 2021, 581B, P. 566-575.
  9. Morton W, et al., Modeling Au Nanostar Geometry in Bulk Solutions. The Journal of Physical Chemistry C. 2023.
  10. Damrongrak, K., et al., Delivery of acetogenin-enriched Annona muricata Linn leaf extract by folic acid-conjugated and triphenylphosphonium-conjugated poly (glycerol adipate) nanoparticles to enhance toxicity against ovarian cancer cells, International Journal of Pharmaceutics, 2022, 121636.
  11. Poellmann, MJ., et al., Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients, Biosensors and Bioelectronics, 2023: 115117.
  12. Feldmann, D.P., et al., The impact of microfluidic mixing of triblock micelleplexes on in vitro in vivo gene silencing and intracellular trafficking, Nanotechnology, 2017, 28(22):224001.
  13. Han, Y., et al., Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy, Biomaterials, 2021, V. 275.
  14. Soni, K.S., et al., Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer, Journal of Controlled Release, 2017, V. 264, P. 276-287.
  15. Chen, F., et al., Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA, Biomater. Sci., 2016,4, 167-182.
  16. Veiman, K.-L., et al., PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo, Journal of Controlled Release, 2015, 209: 238-247.
  17. Guarnieri, D., et al., Tumor‐activated prodrug (TAP)‐conjugated nanoparticles with cleavable domains for safe doxorubicin delivery, Biotechnology and Bioengineering, 2015, 112(3): 601-611.
  18. Chen, Q., et al., Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy, Journal of Controlled Release, 2020; 323:179-90.
  19. Post, A., et al., Elucidation of Endothelial Cell Hemostatic Regulation with Integrin-Targeting Hydrogels, Annals of biomedical engineering, 2019.
  20. Ghuman, H., et al., ECM hydrogel improves the delivery of PEG microsphere-encapsulated neural stem cells and endothelial cells into tissue cavities caused by stroke, Brain Research Bulletin, 2021, V. 168, P. 120-137.
  21. Rezaeeyazdi, M., et al., Engineering hyaluronic acid-based cryogels for CD44-mediated breast tumor reconstruction, Materials Today Bio, 2022.
  22. Koh, R. H, et al., Bioceramic-mediated chondrocyte hypertrophy promotes calcified cartilage formation for rabbit osteochondral defect repair, Bioactive Materials, 2024, V. 40, P. 306-317. Keywords: Bioceramic; Whitlockite; Bilayer scaffold; Chondrocyte hypertrophy; Osteochondral defect repair; acrylate-PEG-N-hydroxysuccinimide ester (acrylate-PEG-NHS)
  23. Xu, X., et al., Efficient and targeted drug/siRNA co-delivery mediated by reversibly crosslinked polymersomes toward anti-inflammatory treatment of ulcerative colitis (UC), Nano Research, 2019, 1-9.
  24. Hao, Y., et al., Tumor penetrating Janus prodrug nanoassemblies for enhanced synergistic chemotherapy and photodynamic therapy of colon cancer, Materials & Design, 2024, v. 241. Keywords: Tumor penetrating; Prodrug; Nanoassemblies; Chemotherapy; Photodynamic therapy; Mal-PEG-NH2
  25. Nourollahian, T., et al., Targeted doxorubicin-loaded core–shell copper peroxide-mesoporous silica nanoparticles for combination of ferroptosis and chemotherapy of metastatic breast cancer, International Journal of Pharmaceutics, 2024, V. 662. Keywords: Chemotherapy; Doxorubicin; Mesoporous organosilica; Ferroptosis; Copper peroxide; H2O2 self-supplying; pH responsive; COOH-PEG-Maleimide
  26. Cho, W., et al., Nanofibril guided spheroid formation for enhanced pluripotency and differentiation of human induced pluripotent stem cells, Chemical Engineering Journal, 2024, V. 492. Keywords: Cell–cell interactions; Induced pluripotent stem cells; Three-dimensional microenvironment; Nanofiber; Electrospinning; Maleimide polyethylene glycol N-hydroxysuccinimide; MAL–PEG–NHS
  27. JNi, J., et al., PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases, Journal of Controlled Release, 2021, V. 329, P. 934-947.
  28. Wang, P., et al., Precise gene delivery systems with detachable albumin shell remodeling dysfunctional microglia by TREM2 for treatment of Alzheimer’s disease, Biomaterials, 2022, V. 281.
  29. Fonseca, DR, et al., Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomaterialia. 2022, 137:186-98.
  30. Cheng, Y., et al, Light-switchable diphtherin transgene system combined with losartan for triple negtative breast cancer therapy based on nano drug delivery system. International Journal of Pharmaceutics, 2022, p.121613.
  31. Jiang, H., et al., Multimodal theranostics augmented by transmembrane polymer-sealed nano-enzymatic porous MoS2 nanoflowers, International Journal of Pharmaceutics, 2020, 586, 119606.
  32. Narvaez-Ortiz, H. Y., et al., Unconcerted conformational changes in Arp2/3 complex integrate multiple activating signals to assemble functional actin networks, Current Biology, 2022, 32(5).
  33. Khare, R., et al., Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors, J. Virology, 2012, 86(4) p: 2293-2301.
  34. Wen, M., et al., Performance of TMC-g-PEG-VAPG/miRNA-145 complexes in electrospun membranes for target-regulating vascular SMCs, Colloids and Surfaces B: Biointerfaces, 2019, 182.
  35. Kim, K.L., et al., Systematic detection of m6A-modified transcripts at single-molecule and single-cell resolution, Cell Reports Methods, 2021, V.1 (5).
  36. Mertgen, A.S., et al., A low-fouling, self-assembled, graft co-polymer and covalent surface coating for controlled immobilization of biologically active moieties, Applied Surface Science, 2022.
  37. Badkas, A., et al., Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery, Colloids and Surfaces B: Biointerfaces, 2018, V. 162, P. 271-278.
  38. Ju, L., et al., Von Willebrand factor-A1 domain binds platelet glycoprotein Ibα in multiple states with distinctive force-dependent dissociation kinetics, Thrombosis Research, 2015, V. 136:3, P. 606-612.
  39. Alpsoy, L., et al., Synthesis and Characterization of Carboxylated Luteolin (CL)-Functionalized SPION, Journal of Superconductivity and Novel Magnetism, 2017.
  40. Guo, L.Y., et al., Skin-safe nanophotosensitizers with highly-controlled synthesized polydopamine shell for synergetic chemo-photodynamic therapy, Journal of Colloid and Interface Science, 2022, 616, pp.81-92.
  41. Sanna, V., et al., Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition, European Journal of Medicinal Chemistry, 2022, 114121.
  42. Li, H., et al., Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma, Biomaterials, 2017.
  43. Stefanick, J.F., et al., Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity, Nanoscale, 2019, 11(10):4414-27.
  44. Lim, YGet al., Calcium-binding near-infrared fluorescent nanoprobe for bone tissue imaging. Journal of Industrial and Engineering Chemistry, 2020, 89:442-7.
  45. Lv, F., et al., Enhanced mucosal penetration and efficient inhibition efficacy against cervical cancer of PEGylated docetaxel nanocrystals by TAT modification, Journal of Controlled Release, 2021, V. 336, P. 572-582.
  46. Chen, Q., et al., Deep tumor‐penetrated nanosystem eliminates cancer stem cell for highly efficient liver cancer therapy, Chemical Engineering Journal, 2021, V. 421 (2).
  47. Xia, C., et al., Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase A silencing for enhanced cancer immunochemotherapy, Journal of Controlled Release, 2021, V. 335, P. 557-574.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.